The USC Norris Comprehensive Cancer Center at the University of Southern California was founded in 1971 and has been continuously supported by a Cancer Center Support Grant since 1973. It has developed into a major regional and national resource for cancer research, treatment, prevention and education. Center facilities have been built and developed with support from the NCI, the University and the Kenneth Norris Jr. Cancer Hospital, which is an integral part of the Cancer Center. The Center underwent a major expansion with the addition of the Norman Topping Tower in 1996 and the Harlyne Norris Research Tower in 2007. The Center's 198 members are organized into five thematic and five translational research programs, including a """"""""bridge"""""""" program in developmental therapeutics. The thematic programs are headed by senior investigators in the fields of molecular genetics, epigenetics and regulation, tumor microenvironment, cancer epidemiology and cancer control research. The translational programs, which provide focus to our transdisciplinary research efforts, are in developmental therapeutics, genitourinary cancers, gastrointestinal cancers, women's cancers and leukemia and lymphoma. This application is for: 1) partial salary support for the Center's senior leadership, who are responsible for planning and overseeing our research efforts;2) support for program planning and evaluation to keep the Center at the forefront of cancer research;3) support for the administrative infrastructure of the Center;4) partial support for the Center's 11 shared resources which facilitate the conduct of our peer-reviewed research;and 5) support for developmental funds to help us recruit new investigators in areas we have targeted for expansion and to fund innovative pilot projects. Continued funding from the Cancer Center Core Support Grant will allow us to build on our strengths in basic and population-based research and to translate our underlying expertise into strong, peer-reviewed funded research programs focused on cancers of major consequence in this country. Cancer Center members currently hold grants totaling $125 million in direct costs, with $43 million of that coming from NCI (all exclusive of the CCSG).

Public Health Relevance

The USC Norris Comprehensive Cancer Center provides the infrastructure and resources to facilitate and foster translational research for the development of more effective prevention, diagnosis, treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-38
Application #
8424831
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1996-12-01
Project End
2015-11-30
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$5,870,229
Indirect Cost
$2,134,690
Name
University of Southern California
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Bensman, Timothy J; Jayne, Jordanna G; Sun, Meiling et al. (2017) Efficacy of Rhesus Theta-Defensin-1 in Experimental Models of Pseudomonas aeruginosa Lung Infection and Inflammation. Antimicrob Agents Chemother 61:
Thomas, Duncan C (2017) Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer. Epidemiology 28:470-478
Thomas, Duncan C (2017) What Does ""Precision Medicine"" Have to Say About Prevention? Epidemiology 28:479-483
Schwitzer, Emily; Orlow, Irene; Zabor, Emily C et al. (2017) No association between prediagnosis exercise and survival in patients with high-risk primary melanoma: A population-based study. Pigment Cell Melanoma Res 30:424-427
Okazaki, Satoshi; Stintzing, Sebastian; Sunakawa, Yu et al. (2017) Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer 141:1222-1230
Liang, Gangning; Weisenberger, Daniel J (2017) DNA methylation aberrancies as a guide for surveillance and treatment of human cancers. Epigenetics 12:416-432
Kim, Yong-Mi; Gang, Eun-Ji; Kahn, Michael (2017) CBP/Catenin antagonists: Targeting LSCs' Achilles heel. Exp Hematol 52:1-11
Reid, Brett M; Permuth, Jennifer B; Chen, Y Ann et al. (2017) Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 26:116-125
Poulard, Coralie; Bittencourt, Danielle; Wu, Dai-Ying et al. (2017) A post-translational modification switch controls coactivator function of histone methyltransferases G9a and GLP. EMBO Rep 18:1442-1459
Tokunaga, Ryuma; Zhang, Wu; Naseem, Madiha et al. (2017) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev 63:40-47

Showing the most recent 10 out of 739 publications